カテゴリ： GlobalData, アメリカ, 企業調査

ArQule Inc (ARQL)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：ArQule Inc (ARQL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012283
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：61
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including activated checkpoint therapy platform and c-met survival protein platform. Its lead product candidate, ARQ 197 (tivantinib), an inhibitor of the c-Met receptor tyrosine kinase, is undergoing clinical-stage development. The other product pipeline of the company includes ARQ 087 is a multi-kinase inhibitor, ARQ 092 is an Akt inhibitor, ARQ 751 is a next-generation inhibitor of Akt, ARQ 761 is an activator of the damage response pathway, , ARQ 531 is a B-cell malignancies and ARQ 087 is an inhibitor of fibroblast growth factor receptor. ArQule is headquartered in Burlington, Massachusetts, the US.

ArQule Inc (ARQL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ArQule Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
ArQule Raises USD15.7 Million in Private Placement of Common Stock 11
Partnerships 12
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12
Licensing Agreements 13
Daiichi Sankyo Exercises Option To Obtain License For ARQ 092 From ArQule 13
Equity Offering 15
ArQule to Raise Funds in Secondary Offering of Shares 15
ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 16
ArQule to Raise Up to USD30 Million in Issue of Shares 17
ArQule Raises USD15.3 Million in Private Placement of Shares 18
ArQule Completes Public Offering Of Common Stock For US$60 Million 19
ArQule Completes An Underwritten Public Offering Of Its Common Stock For US$49.51 Million 21
ArQule Inc – Key Competitors 23
ArQule Inc – Key Employees 24
ArQule Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Nov 09, 2017: ArQule Reports Third Quarter 2017 Financial Results 26
Aug 04, 2017: ArQule Reports Second Quarter 2017 Financial Results 28
May 03, 2017: Arqule Reports First Quarter 2017 Financial Results 29
Mar 07, 2017: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results 30
Nov 07, 2016: ArQule Reports Third Quarter 2016 Financial Results 32
Aug 03, 2016: ArQule Reports Second Quarter 2016 Financial Results 34
May 04, 2016: ArQule Reports First Quarter 2016 Financial Results 36
Feb 29, 2016: ArQule Reports Fourth Quarter and Full Year 2015 Financial Results 38
Product News 40
06/30/2016: ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer 40
06/23/2016: ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer 41
06/07/2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases 42
06/03/2017: ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology Annual Meeting 43
05/17/2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting 44
Product Approvals 45
Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome 45
Clinical Trials 46
Nov 21, 2017: ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma 46
Jul 11, 2017: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies 47
Jun 23, 2017: ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 48
May 18, 2017: ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 49
May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting 50
May 17, 2017: ArQule to Present Clinical Data on ARQ-761 at the 2017 American Society of Clinical Oncology Annual Meeting 51
Apr 11, 2017: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 52
Dec 04, 2016: Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting 53
Dec 03, 2016: Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting 54
Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 55
Jul 18, 2016: ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference 56
Mar 22, 2016: Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma 57
Jan 28, 2016: ArQule Provides Update on ARQ 092 58
Jan 28, 2016: ArQule Provides Update on ARQ 751 59
Jan 25, 2016: ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
ArQule Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ArQule Inc, Deals By Therapy Area, 2011 to YTD 2017 9
ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ArQule Raises USD15.7 Million in Private Placement of Common Stock 11
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12
Daiichi Sankyo Exercises Option To Obtain License For ARQ 092 From ArQule 13
ArQule to Raise Funds in Secondary Offering of Shares 15
ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 16
ArQule to Raise Up to USD30 Million in Issue of Shares 17
ArQule Raises USD15.3 Million in Private Placement of Shares 18
ArQule Completes Public Offering Of Common Stock For US$60 Million 19
ArQule Completes An Underwritten Public Offering Of Its Common Stock For US$49.51 Million 21
ArQule Inc, Key Competitors 23
ArQule Inc, Key Employees 24

★海外企業調査レポート[ArQule Inc (ARQL)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Creganna Medical：企業の戦略的SWOT分析
    Creganna Medical - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • InFlectis BioScience-製薬・医療分野：企業M&A・提携分析
    Summary InFlectis BioScience (InFlectis) is a drug discovery company that discovers and develops small molecule drugs that target the unfolded protein response (UPR) to treat misfolding protein disorders such as age-related and neurodegenerative diseases. The company’s product lead candidate IFB-088 …
  • OpenHydro Group Limited-エネルギー分野：企業M&A・提携分析
    Summary OpenHydro Group Limited (OpenHydro), a subsidiary of DCNS S.A. designs and manufactures marine turbines for generating renewable energy from tidal streams. The company offers installation and maintenance services for the construction of tidal farms using its Open-Centre Turbine technology. T …
  • Voith GmbH & Co KGaA：企業の戦略的SWOT分析
    Voith GmbH & Co KGaA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Tadano Ltd：企業の戦略・SWOT・財務分析
    Tadano Ltd - Strategy, SWOT and Corporate Finance Report Summary Tadano Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • The Williams Companies, Inc.：企業の戦略・SWOT・財務分析
    The Williams Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Williams Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Pulse Seismic Inc (PSD)：企業の財務・戦略的SWOT分析
    Summary Pulse Seismic Inc (Pulse), formerly Pulse Data Inc is a provider of seismic data library for oil and gas exploration. The company acquires, markets and licenses 2D and 3D seismic data to the western Canadian energy sector. It offers services such as project cost tracking, scouting, geophysic …
  • Prolung Inc (LUNG)：医療機器：M&Aディール及び事業提携情報
    Summary Prolung Inc(Prolung) formerly known as Fresh Medical Laboratories Inc, is a medical device company that offers diagnostic services. The company offers electro pulmonary nodule scanner system used for the non invasive early diagnostics of different types of diseases. Its EPN system consists o …
  • Enviva Partners LP (EVA)：企業の財務・戦略的SWOT分析
    Enviva Partners LP (EVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • CIncinnati Children’s Hospital Medical Center：企業のM&A・事業提携・投資動向
    CIncinnati Children's Hospital Medical Center - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CIncinnati Children's Hospital Medical Center Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, …
  • NSK Ltd.：企業の戦略・SWOT・財務分析
    NSK Ltd. - Strategy, SWOT and Corporate Finance Report Summary NSK Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • NIKE Inc：戦略・SWOT・企業財務分析
    NIKE Inc - Strategy, SWOT and Corporate Finance Report Summary NIKE Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • TaiDoc Technology Corporation (4736)：企業の財務・戦略的SWOT分析
    TaiDoc Technology Corporation (4736) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Immatics Biotechnologies GmbH-製薬・医療分野：企業M&A・提携分析
    Summary Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs …
  • U-Shin Ltd.：企業の戦略的SWOT分析
    U-Shin Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Chembio Diagnostic Inc (CEMI)：企業の財務・戦略的SWOT分析
    Chembio Diagnostic Inc (CEMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Mahanagar Telephone Nigam Ltd (MTNL)：企業の財務・戦略的SWOT分析
    Mahanagar Telephone Nigam Ltd (MTNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Vikas WSP Ltd (VIKASWSP)：企業の財務・戦略的SWOT分析
    Vikas WSP Ltd (VIKASWSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Invenergy LLC：企業の発電所・SWOT分析2018
    Invenergy LLC - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Hera SpA (HER)：企業の財務・戦略的SWOT分析
    Hera SpA (HER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆